Page last updated: 2024-10-27

flutamide and Cancer of the Fallopian Tube

flutamide has been researched along with Cancer of the Fallopian Tube in 1 studies

Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Gruessner, C	1
Gruessner, A	1
Glaser, K	1
AbuShahin, N	1
Zhou, Y	1
Laughren, C	1
Wright, H	1
Pinkerton, S	1
Yi, X	1
Stoffer, J	1
Azodi, M	1
Zheng, W	1
Chambers, SK	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
A Prospective, Phase IIA Study of the Effect of Flutamide (125 MG/DAY) Taken for 6 Weeks on Expression of Potential Biomarkers of Flutamide Action in the Ovaries of Women at Increased Risk for Ovarian Cancer[NCT00699907]			Phase 2	127 participants (Actual)	Interventional	2005-01-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Colony Stimulating Factor (CSF-1) Expression in Ovarian Endosalpingiosis

"CSF-1 levels were measured by immunohistochemistry (IHC).~The modified H-Score assess extent of nuclear immunoreactivity applicable to steroid receptors.~The modified H-scores total range is 0-300. A lower modified H-score indicates weakly staining nuclei. A higher modified H-score indicated strongly staining nuclei.~This applies to all measures." (NCT00699907)
Timeframe: Surgery

Intervention	Modified H-Score (Median)
Treatment Arm	5
High Risk Arm	130
Low Risk Arm	50

Colony Stimulating Factor (CSF-1) Expression in Ovarian Epithelium

CSF-1 levels were measured by immunohistochemistry (IHC). (NCT00699907)
Timeframe: Surgery

Intervention	Histo-score (H-Score) (Median)
Treatment Arm	0
High Risk Arm	50
Low Risk Arm	0

Colony Stimulating Factor (CSF-1) Expression in Ovarian Stroma

CSF-1 levels were measured by immunohistochemistry (IHC). (NCT00699907)
Timeframe: Surgery

Intervention	Histo-score (H-Score) (Median)
Treatment Arm	5
High Risk Arm	40
Low Risk Arm	35

Colony Stimulating Factor-1 Receptor (CSF-1R) Expression in Ovarian Endosalpingiosis

CSF-1R levels were measured by immunohistochemistry (IHC). (NCT00699907)
Timeframe: Surgery

Intervention	Histo-score (H-Score) (Median)
Treatment Arm	15
High Risk Arm	160
Low Risk Arm	75

Colony Stimulating Factor-1 Receptor (CSF-1R) Expression in Ovarian Epithelium

CSF-1R levels were measured by immunohistochemistry (IHC). (NCT00699907)
Timeframe: Surgery

Intervention	Histo-score (H-Score) (Median)
Treatment Arm	0
High Risk Arm	40
Low Risk Arm	20

Colony Stimulating Factor-1 Receptor (CSF-1R) Expression in Ovarian Stroma

CSF-1R levels were measured by immunohistochemistry (IHC). (NCT00699907)
Timeframe: Surgery

Intervention	Histo-score (H-Score) (Median)
Treatment Arm	20
High Risk Arm	40
Low Risk Arm	53

Tyrosine Kinase V-erb-b2 Erythroblastic Leukemia Viral Oncogene Homolog-4 (ErbB4) Expression in Ovarian Endosalpingiosis

ErbB4 levels were measured by immunohistochemistry (IHC). (NCT00699907)
Timeframe: Surgery

Intervention	Histo-score (H-Score) (Median)
Treatment Arm	5
High Risk Arm	60
Low Risk Arm	10

Tyrosine Kinase V-erb-b2 Erythroblastic Leukemia Viral Oncogene Homolog-4 (ErbB4) Expression in Ovarian Epithelium

ErbB4 levels were measured by immunohistochemistry (IHC). (NCT00699907)
Timeframe: Surgery

Intervention	Histo-score (H-Score) (Median)
Treatment Arm	0
High Risk Arm	55
Low Risk Arm	0

Tyrosine Kinase V-erb-b2 Erythroblastic Leukemia Viral Oncogene Homolog-4 (ErbB4) Expression in Ovarian Stroma

ErbB4 levels were measured by immunohistochemistry (IHC). (NCT00699907)
Timeframe: Surgery

Intervention	Histo-score (H-Score) (Median)
Treatment Arm	10
High Risk Arm	90
Low Risk Arm	30

Trials

1 trial available for flutamide and Cancer of the Fallopian Tube

Article	Year
Flutamide and biomarkers in women at high risk for ovarian cancer: preclinical and clinical evidence. Cancer prevention research (Philadelphia, Pa.), 2014, Volume: 7, Issue:9 Topics: Adult; Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Area Under Curve; Biomarkers,	2014